PSA Levels Lower in Obese Men
Prostate cancer screening may be adversely affected by increased body mass index

By Megan Rauscher

Tuesday, November 20 (Reuters Health) - A larger blood volume resulting in hemodilution may be responsible for the lower prostate-specific antigen (PSA) levels observed in overweight and obese men compared with normal weight men, new findings suggest.

Recent evidence has indicated that prostate cancer screening may be adversely affected by increased body mass index (BMI), the researchers note in the November 21 issue of the Journal of the American Medical Association.

In a retrospective study of nearly 14,000 men with prostate cancer who underwent radical prostatectomy, Dr. Stephen J. Freedland from Duke University Medical Center, Durham, North Carolina, and colleagues found that men with a BMI of 35 or greater had 21-percent to 23-percent greater blood volume than normal-weight men.

Obese men also had lower PSA values, as others have shown. In this study, men with a BMI of 35 or greater had 11-percent to 21-percent lower PSA concentrations relative to normal-weight men.

"But very interestingly," Freedland told Reuters Health, "when we looked at the amount of PSA in the blood, we actually saw no association between obesity level and the amount of PSA in the blood. Obese men had just as much PSA in the bloodstream or even slightly more and yet their concentrations were lower."

This suggests that circulating PSA in obese men is diluted by their larger plasma volume.

"The consequence is that we may actually be missing cancers in obese men," Freedland said. "It's not that PSA is a bad test for obese men; it's just that we need to learn how to use it better, and when we do that I think we are going to be able to detect these cancers earlier in obese men."

SOURCE: Journal of the American Medical Association, November 21, 2007.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Would you like to receive prostate cancer news by email? Subscribe to NewsPulse